GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2022-10-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 300
- Registration Number
- NCT03562195
- Locations
- 🇨🇳
GSK Investigational Site, Tianjin, China
Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With Varying Degrees of Hepatic Impairment and in Matched Control Subjects With Normal Hepatic Function
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2021-04-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 25
- Registration Number
- NCT03562117
- Locations
- 🇺🇸
GSK Investigational Site, Orlando, Florida, United States
An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 76
- Registration Number
- NCT03557281
- Locations
- 🇿🇦
GSK Investigational Site, Cape Town, South Africa
NUCALA® Special Drug Use Investigation (EGPA, Long-term)
- Conditions
- Churg-Strauss Syndrome
- Interventions
- First Posted Date
- 2018-06-14
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 300
- Registration Number
- NCT03557060
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Bioequivalence Study Between Levocetirizine Oral Disintegrating Tablet (ODT) and Levocetirizine Immediate Release Tablet (IRT)
- Conditions
- Rhinitis
- Interventions
- First Posted Date
- 2018-06-14
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 72
- Registration Number
- NCT03555890
- Locations
- 🇯🇵
GSK Investigational Site, Fukuoka, Japan
A Pivotal Study to Assess the Effectiveness of Nasal Dilator (Breathe Right Nasal Strips)
- Conditions
- Congestion, Nasal
- Interventions
- Device: Breathe Right Tan (small/medium) nasal stripsOther: Placebo nasal strip
- First Posted Date
- 2018-06-07
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 130
- Registration Number
- NCT03549130
- Locations
- 🇺🇸
Concentrics Research, Indianapolis, Indiana, United States
🇺🇸TKL Research Inc, Paramus, New Jersey, United States
A Pivotal Subjective Sleep Study of a Nasal Dilator (Breathe Right Tan)
- Conditions
- Congestion, Nasal
- Interventions
- Device: Breathe Right Tan (small/medium) nasal stripsOther: Placebo nasal strip
- First Posted Date
- 2018-06-07
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 140
- Registration Number
- NCT03549117
- Locations
- 🇺🇸
Essex Testing Clinic, Inc, Verona, New Jersey, United States
🇺🇸Radiant Research - Cincinnati, Cincinnati, Ohio, United States
To Assess the Bioequivalence of the 4mg Prototype Mini Nicotine Lozenge to the Reference Product (Nicorette) in Healthy Smokers
- Conditions
- Tobacco Use Disorder
- Interventions
- First Posted Date
- 2018-06-01
- Last Posted Date
- 2019-12-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 37
- Registration Number
- NCT03543137
- Locations
- 🇺🇸
GSK Investigational Site, Lincoln, Nebraska, United States
To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2018-06-01
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 153
- Registration Number
- NCT03544281
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Chronic Obstructive Pulmonary Disease (COPD) Dual Therapy Burden of Illness
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Other: FLUT/SALOther: UMEC/VIOther: CATOther: mMRCDevice: ElliptaDevice: Diskus
- First Posted Date
- 2018-06-01
- Last Posted Date
- 2020-08-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 789
- Registration Number
- NCT03543176
- Locations
- 🇺🇸
GSK Investigational Site, Durham, North Carolina, United States